Doliprane Pediatric Suspension Recall: Graduations on Droppers May Fade, Raising Dosage Concerns
Parents and caregivers should be aware of a recall affecting certain lots of Doliprane 2.4% oral suspension, a common acetaminophen medication for infants and young children. The recall, announced on February 23, 2026, by the French National Agency for the Safety of Medicines and Health Products (ANSM), stems from a manufacturing defect that could lead to inaccurate dosing. Specifically, the markings on the droppers provided with the medication may gradually disappear after being rinsed with warm or hot water. This poses a potential risk of accidental overdose, particularly for children weighing between 3 and 26 kilograms.
The ANSM emphasizes that the quality of the medication itself is not compromised. However, the inability to accurately measure the correct dosage due to faded markings presents a serious safety concern. Opella Healthcare France, the manufacturer, is working with the ANSM to recall 27 affected lots. Parents who have purchased Doliprane 2.4% suspension from one of these lots are urged to return it to their pharmacy for a free replacement. The lot number can be found on the packaging, either on the box or directly on the bottle.
Understanding the Risk: Acetaminophen Dosage and Infants
Acetaminophen, also known as paracetamol, is a widely used medication to reduce fever and relieve pain in children. Accurate dosing is crucial, as both underdosing and overdosing can be harmful. Overdosing on acetaminophen can lead to serious liver damage, even in otherwise healthy children. The risk is particularly acute in infants and young children, whose livers are still developing and are more vulnerable to the toxic effects of the drug. According to the National Institutes of Health, acetaminophen is processed by the liver, and exceeding the recommended dosage can overwhelm the organ’s capacity to metabolize the medication safely.
The Doliprane 2.4% suspension is specifically formulated for use in infants and young children. The dropper is designed to allow for precise measurement of the liquid medication, ensuring that the child receives the correct dose based on their weight. The fading of the graduations on the dropper compromises this precision, potentially leading to errors in dosage administration. The ANSM’s recall specifically addresses this risk for children within the 3-26 kg weight range, as this is the population for whom accurate dosing with the provided dropper is most critical.
How to Check if Your Doliprane is Affected
Determining whether your Doliprane 2.4% suspension is part of the recall is straightforward. The lot number is printed on the outer packaging of the box, typically on the back within a white frame, alongside the expiration date. This proves also printed on the label affixed directly to the bottle. Parents should carefully examine their existing supply of Doliprane and compare the lot number to the list of recalled lots published by the ANSM. The ANSM website provides a comprehensive list of affected lot numbers and detailed instructions on how to proceed with a return or exchange.
What to Do If You Have an Affected Lot
If you discover that your Doliprane 2.4% suspension is from one of the recalled lots, the ANSM advises that you do not use it. Instead, return the product to your local pharmacy for a free replacement. Pharmacists are prepared to handle these returns and provide a new, unaffected bottle of Doliprane or, if preferred, recommend an alternative acetaminophen product. It is important to emphasize that the recall is a precautionary measure to ensure patient safety, and parents should not hesitate to seek a replacement if they have a potentially affected product.
While the recall focuses on the dropper issue, it’s a solid reminder for all parents and caregivers to always double-check medication dosages, especially for children. The American Academy of Pediatrics offers detailed guidance on safe medication administration for children, including resources on calculating appropriate dosages based on weight and age.
Broader Context: Paracetamol Safety and Regulation
This recall highlights the importance of rigorous quality control in pharmaceutical manufacturing and the vigilance of regulatory agencies like the ANSM. Paracetamol, while generally safe when used as directed, is a common cause of medication-related adverse events, particularly due to accidental overdoses. In 2023, the European Health Journalism Award recognized reporting on medication safety, underscoring the growing focus on this critical public health issue.
The ANSM’s prompt action in initiating this recall demonstrates its commitment to protecting public health. The agency regularly monitors the safety of medications available in France and takes swift action to address any potential risks. This includes conducting inspections of manufacturing facilities, reviewing adverse event reports, and issuing recalls when necessary. The agency’s website serves as a valuable resource for consumers seeking information about medication safety and recalls.
Looking Ahead: Monitoring and Prevention
The ANSM will continue to monitor the situation and provide updates as needed. Opella Healthcare France is expected to implement corrective measures to prevent similar issues from occurring in the future. This may involve changes to the manufacturing process or the design of the dropper. Parents and caregivers are encouraged to stay informed about medication recalls and to follow the guidance of healthcare professionals regarding medication safety.
The next step in this process will be the completion of the recall and the implementation of corrective actions by the manufacturer. The ANSM will likely publish a follow-up report detailing the findings of its investigation and the steps taken to address the issue. In the meantime, parents should prioritize the safety of their children by checking their Doliprane supply and seeking a replacement if necessary.
Have questions or concerns about this recall? Share your thoughts in the comments below, and please share this article with your network to help spread awareness.